Seed · Biotech · Leuven, Belgium · 31–35 employees
AstriVax Therapeutics is a Leuven-based clinical-stage biopharmaceutical spin-off from KU Leuven that has raised a record €30 M seed round to build a first-in-class plug-and-play DNA-launched vaccine and immunotherapy platform addressing major infectious diseases; its proprietary Launch-iT technology is designed to generate thermostable viral vectors that elicit broad immune responses for both prophylactic and therapeutic applications, and the company’s pipeline includes Phase I clinical studies for chronic hepatitis B immunotherapy and other high-impact targets, positioning it at the forefront of next-generation immune interventions.
No open roles listed right now.